echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Biogen Fampridine Sustained-Release Tablets are approved to improve the walking ability of adult patients with multiple sclerosis...

    Biogen Fampridine Sustained-Release Tablets are approved to improve the walking ability of adult patients with multiple sclerosis...

    • Last Update: 2021-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 14, 2021, Bojian Company announced that Fampridine Sustained-Release Tablets have been officially approved by the National Medical Products Administration for the improvement of multiple sclerosis (hereinafter referred to as MS) combined with walking disorder (EDSS score 4-7) in adult patients Walking ability.


    The drug review of the National Medical Products Administration referred to three global phase 3, randomized, double-blind, placebo-controlled confirmatory studies.


    In May 2018, MS was included in the "First List of Rare Diseases.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.